Metabolic Imaging Phenotype Using Radiomics of [18F]FDG PET/CT Associated with Genetic Alterations of Colorectal Cancer

2018 ◽  
Vol 21 (1) ◽  
pp. 183-190 ◽  
Author(s):  
Shang-Wen Chen ◽  
Wei-Chih Shen ◽  
William Tzu-Liang Chen ◽  
Te-Chun Hsieh ◽  
Kuo-Yang Yen ◽  
...  
2015 ◽  
Vol 40 (8) ◽  
pp. 621-626 ◽  
Author(s):  
Shang-Wen Chen ◽  
Chien-Yu Lin ◽  
Cheng-Man Ho ◽  
Ya-Sian Chang ◽  
Shu-Fen Yang ◽  
...  

2012 ◽  
pp. 249-254
Author(s):  
Maria V. Mattoli ◽  
Giorgio Treglia ◽  
Lucia Leccisotti ◽  
Alessandro Giordano

Introduction: 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) plays a key role in oncology, and it is now being used increasingly to diagnose, characterize, and monitor disease activity in inflammatory disorders, including vasculitis. Unfortunately, its role in the management of vasculitis is still not well-defined, and clinicians are often unsure how this metabolic imaging technique should be used in these diseases, although its usefulness in diagnosing large-vessel vasculitis has been clearly demonstrated. Materials and methods: We reviewed the literature about the use of PET/CT in the management of vasculitis in an attempt to identify the applications and the limitations of this technique in clinical practice. Results and discussion: Our literature review revealed that 18F-FDG PET/CT is a useful tool for diagnosing vasculitis (especially when the symptoms of the disease are non-specific); guiding biopsy procedures (areas with high glucose consumption); evaluating disease extension; and monitoring treatment responses. The main limitations of this method are the relatively low spatial resolution of the tomograph, which can lead to false-negative results in the presence of small-vessel vasculitis, and risk of false positive results, especially those related to the presence of atherosclerosis and to post-treatment vascular remodeling.


2010 ◽  
Vol 71 (5) ◽  
pp. AB345
Author(s):  
Si Hyung Lee ◽  
Kyeong Ok Kim ◽  
Byung-Ik Jang ◽  
Tae Nyeun Kim ◽  
Seongwoo Jeon ◽  
...  

2013 ◽  
Vol 37 (6) ◽  
pp. 1094-1097 ◽  
Author(s):  
William Makis ◽  
David Kurzencwyg ◽  
Marc Hickeson

2017 ◽  
Vol 28 ◽  
pp. iii12
Author(s):  
Angelica Nazarian ◽  
Zoe Andrada ◽  
Joanne Thomas ◽  
Sudipta Sureshbabu ◽  
Nathaniel Berman ◽  
...  

2013 ◽  
Vol 37 (3) ◽  
pp. 536-541 ◽  
Author(s):  
Alexandros Georgakopoulos ◽  
Nikoletta Pianou ◽  
Nikolaos Kelekis ◽  
Sofia Chatziioannou

2020 ◽  
Vol 28 (2) ◽  
pp. 119
Author(s):  
Renata Milardovic ◽  
Nermina Beslic ◽  
Amera Sadija ◽  
Sejla Ceric ◽  
Melika Bukvic ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  

2020 ◽  
Vol 49 (1) ◽  
pp. 1
Author(s):  
Emir Sokolović ◽  
Timur Cerić ◽  
Šejla Cerić ◽  
Semir Bešlija ◽  
Sandra Vegar-Zubović ◽  
...  

<p><strong>Objective. </strong>The aim of the study was to evaluate the prognostic value of the maximum standardized uptake value (SUVmax) of 18F-Fluorodeoxyglucose (18F-FDG) PET/CT in patients with metastatic colorectal cancer, and to compare it with classical prognostic markers.</p><p><strong>Materials and Methods. </strong>The study included 70 patients with metastatic colorectal cancer who had not been treated for the metastatic disease. The patients underwent 18F-FDG PET/CT as part of their routine diagnostic reevaluation. During the analysis, the value of the largest tumor diameter and SUVmax was determined for the lesion with the highest SUVmax observed. The values of CEA and CA 19-9 were recorded 7 days before the PET/CT analysis.</p><p><strong>Results. </strong>SUVmax and Carbohydrate antigen (CA)19-9 were found to be independent prognostic markers of disease progression within 12 months. Based on the Receiver Operating Characteristics (ROC) curve analysis, the patients could be divided into two groups: SUVmax≤4.1 vs. SUVmax&gt;4.1. Patients with SUVmax values of 4.1 or less had significantly better progression-free survival within 12 months with an HR (95% CI) of 2.97 (1.4-6.3), relative to patients with SUVmax values above 4.1.</p><p><strong>Conclusion. </strong>SUVmax may be used as a novel prognostic marker of disease progression among patients with metastatic colorectal cancer. Values of SUVmax can be used to select patients with a more aggressive type of disease and higher risk for progression within 12 months of PET/CT analysis.</p>


Sign in / Sign up

Export Citation Format

Share Document